<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
CUBIST PHARMACEUTICALS, INC.
(Name of Issuer)
COMMON STOCK $.001 PAR VALUE
(Title of Class of Securities)
229 678 610
(CUSIP Number)
GINETTE DEPELTEAU
SOFINOV,
SOCIETE FINANCIERE D'INNOVATION, INC.
1981 MCGILL COLLEGE AVENUE
MONTREAL, QUEBEC H3A 3C7
(514) 847-5901
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
[OCTOBER 29, 1999]
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rules 13d-1 (e), 13d-1(f) or 13d-1(g), check the following
box / /.
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7 for other parties
to whom copies are to be sent.
(Continued on following pages)
- -----------------
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter disclosure
provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
1
<PAGE>
CUSIP No. 229 678 610
- ---------------- ---------------------------------------------------------------
1. NAME OF REPORTING PERSON
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SOFINOV, SOCIETE FINANCIERE D'INNOVATION, INC.
- ---------------- ---------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) / /1
(b) / /2
- ---------------- ---------------------------------------------------------------
3. SEC USE ONLY
- ---------------- ---------------------------------------------------------------
4. SOURCE OF FUNDS*: WC
- ---------------- ---------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) / /3
- ---------------- ---------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
MONTREAL, QUEBEC, CANADA
- --------------------------------- -------- -------------------------------------
NUMBER OF SHARES 7. SOLE VOTING POWER:
BENEFICIALLY 2,997,335(1)
OWNED BY EACH
REPORTING PERSON
WITH
-------- -------------------------------------
SHARED VOTING POWER:
8. --
-------- -------------------------------------
SOLE DISPOSITIVE POWER:
9. 2,997,335
-------- -------------------------------------
SHARED DISPOSITIVE POWER:
10. --
- ---------------- ---------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,997,335
- ---------------- ---------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES / /4
- ---------------- ---------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
16.0%
- ---------------- ---------------------------------------------------------------
14. TYPE OF REPORTING PERSON: CO
- ---------------- ---------------------------------------------------------------
(1) Includes 1,111,112 shares of Common Stock of the Company issuable
upon exercise of a warrant. See Item 4 below.
* SEE INSTRUCTIONS BEFORE FILLING OUT!
2
<PAGE>
CUSIP No. 229 678 610
- ---------------- ---------------------------------------------------------------
1. NAME OF REPORTING PERSON
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC.
- ---------------- ---------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) / /5
(b) / /6
- ---------------- ---------------------------------------------------------------
3. SEC USE ONLY
- ---------------- ---------------------------------------------------------------
4. SOURCE OF FUNDS*: WC
- ---------------- ---------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) / /7
- ---------------- ---------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
MONTREAL, QUEBEC, CANADA
- --------------------------------- -------- -------------------------------------
NUMBER OF SHARES 7. SOLE VOTING POWER:
BENEFICIALLY 2,997,335(1)
OWNED BY EACH
REPORTING PERSON
WITH
-------- -------------------------------------
SHARED VOTING POWER:
8. --
-------- -------------------------------------
SOLE DISPOSITIVE POWER:
9. 2,997,335
-------- -------------------------------------
SHARED DISPOSITIVE POWER:
10. --
- ---------------- ---------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,997,335
- ---------------- ---------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES / /8
- ---------------- ---------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
13. 16.0%
- ---------------- ---------------------------------------------------------------
14. TYPE OF REPORTING PERSON: CO
- ---------------- ---------------------------------------------------------------
(1) Includes 1,111,112 shares of Common Stock of the Company issuable
upon exercise of a warrant. See Item 4 below.
* SEE INSTRUCTIONS BEFORE FILLING OUT!
3
<PAGE>
This Amendment No. 2, dated October 29, 1999, to the statement on
Schedule 13D filed in hard copies with the Securities and Exchange Commission
(the "SEC") on September 23, 1998, as amended by Amendment No. 1 filed with the
SEC on September 14, 1999 (as amended, the "Schedule 13D") is being filed
jointly on behalf of Caisse de depot et placement du Quebec ("CDPQ") and by its
wholly-owned subsidiary, SOFINOV, Societe financiere d'innovation, inc.
("Sofinov") pursuant to Rule 13d-2(a) under the Securities Exchange Act of 1934,
as amended (the "Exchange Act") pursuant to a Joint Filing Agreement dated
October 29, 1999, between CDPQ and Sofinov, a copy of which is attached hereto
as Exhibit 1.
Because this Amendment No. 2 is the first electronic filing via Edgar,
the Schedule 13D is hereby amended and restated as follows:
ITEM 1. SECURITY AND ISSUER.
This Schedule 13D relates to the Common Stock, par value $.001
per share ("Common Stock"), of Cubist Pharmaceuticals, Inc., a
Delaware corporation (the "Company"). The address of the
principal executive offices of the Company is 24 Emily Street,
Cambridge, Massachusetts 02139.
ITEM 2. IDENTITY AND BACKGROUND
This Schedule 13D is filed jointly on behalf of CDPQ, a
corporation without share capital and an agent of the Crown in
right of the Province de Quebec, created by a special act of
the Legislature of the Province de Quebec, and Sofinov, a
legal entity duly incorporated under part 1A of the Companies
ACT (Quebec) and a wholly-owned subsidiary of CDPQ, pursuant
to Rule 13d-1(f)(1) under the Exchange Act.
The principal business address and the principal office
address of each of CDPQ and Sofinov is 1981, Avenue McGill
College, Suite 1330, Montreal, Quebec, H3A 3C7, Canada. The
name, business address, citizenship and present principal
occupation of each director and executive officer of CDPQ and
Sofinov are set forth on Schedule I.
To the best knowledge of CDPQ and Sofinov, none of the persons
listed on Schedule I has, during the last five years, (i) been
convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors) or (ii) been a party to a
civil proceeding of a judicial or administrative body of
competent jurisdiction and as a result of such proceeding was
or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities
subject to, United States federal or state securities laws or
finding any violation with respect to such laws.
4
<PAGE>
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
All the funds required to purchase the Initial Shares (as
defined below) were obtained from the working capital of
Sofinov.
ITEM 4. PURPOSE OF TRANSACTION
Pursuant to a Purchase Agreement (the "Purchase Agreement")
dated September 10, 1998, Sofinov acquired beneficial
ownership of 3,497,335 shares of Common Stock in a private
placement through (i) the purchase of 2,386,223 shares of
Common Stock (the "Initial Shares") with an exercise price as
set forth in Exhibit 2 for an aggregate purchase price of
US$5,287,002 (the "Purchase Price") and (ii) the granting by
the Company to Sofinov of a warrant (the "Warrant")
exercisable in whole or in part into 1,111,112 shares of
Common Stock (the "Warrant Shares") with an expiration date of
September 23, 2003.
Pursuant to the exercise of certain registration rights
granted to Sofinov in connection with the private placement,
the Initial Shares and the Warrant Shares were registered for
resale by Sofinov on a Registration Statement on Form S-3
which was filed with the SEC on September 30, 1998.
On September 14, 1999, Sofinov sold 500,000 Initial Shares for
US$7,627,501, as set forth on Exhibit 3.
Pursuant to the Purchase Agreement, Sofinov has the right to
designate one person to be elected to the board of directors
of the Company. The Company has agreed to take all steps
necessary and appropriate and otherwise use its best efforts
to cause the individual designated by Sofinov to be duly and
properly elected to the board of directors of the Company.
This right will terminate when Sofinov ceases to own at least
thirty-three and one-third percent (33 1/3%) of the Initial
Shares purchased by it under the Purchase Agreement.
Except as specifically set forth in this Item 4, neither CDPQ
nor Sofinov has any plans or proposals which relate to or
would result in any of the actions or effects set forth in
items (a) through (j) of Item 4 of Schedule 13D, although
either of them may develop such plans or proposals.
CDPQ and Sofinov intend to review on a continuing basis their
investment in the Company. As of the date of this Schedule
13D, no determination has been made by CDPQ or Sofinov to
acquire additional shares of Common Stock or dispose of any
shares of Common Stock now held by them, although either of
them may decide to so acquire or dispose of shares of Common
Stock. Any such determination will depend on market conditions
prevailing from time to time and on other conditions which may
be applicable depending on the nature of the transaction or
transactions involved.
5
<PAGE>
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
(a) Sofinov is the direct beneficial owner of 2,997,335 shares of
Common Stock (including the Warrant Shares)(the "Sofinov
Shares"). CDPQ may be deemed to be the indirect, beneficial
owner of the Sofinov Shares. The Sofinov Shares represent
approximately 16.0% of the 17,569,657 shares of Common Stock
of the Company outstanding on the date hereof, based upon
information provided by the company, plus the Warrant Shares.
(b) CDPQ has the power to vote and dispose of the Sofinov Shares.
(c) Except as set forth in this Schedule 13D, none of CDPQ,
Sofinov or, to the best knowledge of CDPQ or Sofinov, any
person named on Schedule I hereto, owns any shares of the
Company's Common Stock, and none has purchased or sold any
shares of the Company's Common Stock during the past 60 days.
(d) Except as set forth in this Schedule 13D, no person is known
by CDPQ or Sofinov to have the right to receive or the power
to direct the receipt of dividends from, or the proceeds from
the sale of, the shares of Common Stock of the Company
beneficially owned by CDPQ and Sofinov.
(e) Not applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
RESPECT TO SECURITIES OF THE ISSUER
Except as set forth in this Schedule 13D, there are no
contracts, arrangements, understandings or relationships
(legal or otherwise) among the persons referred to in Item 2
of this Schedule 13D or between such persons and any other
person with respect to any of the securities of the Company,
including, but not limited to, any relating to the transfer or
voting of any of such securities, finder's fees, joint
ventures, loan or option arrangements, puts or calls,
guarantees of profits, division of profits or loss or the
giving or withholding of proxies.
ITEM 7. MATERIALS TO BE FILED AS EXHIBITS
1. Joint Filing Agreement dated October 29, 1999 by and
between Sofinov and CDPQ.
2. Joint Filing Table of Sales and Purchases of Cubist
Pharmaceuticals, Inc.
3. Joint Filing Table of Dates, Number of Shares sold and
price per Share of Sales.
6
<PAGE>
SIGNATURES
After reasonable inquiry and to the best knowledge and belief of the
undersigned, the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Date: October 29, 1999
SOFINOV, SOCIETE FINANCIERE D'INNOVATION, INC.
By:
------------------------------------------
Name: Ginette Depelteau
Title: Corporate Secretary
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC.
By:
------------------------------------------
Name: Ginette Depelteau
Title: General Secretary - Director
7
<PAGE>
SCHEDULE I
LIST OF EXECUTIVE OFFICERS AND DIRECTORS OF SOFINOV
<TABLE>
<CAPTION>
DIRECTORS BUSINESS ADDRESS PRINCIPAL
OCCUPATION
<S> <C> <C>
Jean-Claude Scraire Caisse de depot et placement du Quebec Chairman
1981, Avenue McGill College
Montreal (Quebec) H3A 3C7
Line Boisvert Caisse de depot et placement du Quebec Director and
1981, Avenue McGill College Portfolio
Montreal (Quebec) H3A 3C7 Manager
Jacques M. Brault Levesque Beaubien Geoffrion Inc. Senior Vice-
1155, Metcalfe, 5(e) etage President
Montreal, (Qubec) H3B 4S9
Denis Dionne SOFINOV, Societe financiere d'innovation, inc. President
1981, Avenue McGill College
Montreal (Quebec) H3A 3C7
Claude Lajeunesse Ryerson Polytechnic University President and
350, Victoria Street Vice Chancellor
Toronto (Ontario) H2M 2V1
Serge Martin Martin International President
500, Place d'Armes, Suite 2910
Montreal, (Qubec) H2Y 2W2
Guy Morneau Regie des rentes du Quebec Chairman of the
2600 boul. Laurieir, bureau 546 Board and
Qubec (Qubec) G1V 4T3 President
Normand Provost Caisse de depot et placement du Quebec Vice-President
1981, Avenue McGill College Coordinator
Montreal (Quebec) H3A 3C7
</TABLE>
8
<PAGE>
SCHEDULE 1
LIST OF EXECUTIVE OFFICERS AND DIRECTORS OF SOFINOV
<TABLE>
<CAPTION>
OFFICERS BUSINESS ADDRESS PRINCIPAL
OCCUPATION
<S> <C> <C>
Jean-Claude Scraire Caisse de depot et placement du Quebec Chairman
1981, Avenue McGill College
Montreal (Quebec) H3A 3C7
Denis Dionne SOFINOV, Societe financiere d'innovation, inc. President
1981, Avenue McGill College
Montreal (Quebec) H3A 3C7
Pierre Pharand SOFINOV, Societe financiere d'innovation, inc. Vice-President
1981, Avenue McGill College
Montreal (Quebec) H3A 3C7
Bertrand Lauzon Caisse de depot et placement du Quebec Vice-President,
1981, Avenue McGill College Finance and Control
Montreal (Quebec) H3A 3C7
Ginette Depelteau Caisse de depot et placement du Quebec Secretary
1981, Avenue McGill College
Montreal (Quebec) H3A 3C7
</TABLE>
9
<PAGE>
SCHEDULE 1
LIST OF EXECUTIVE OFFICERS AND DIRECTORS OF CDPQ
<TABLE>
<CAPTION>
DIRECTORS BUSINESS ADDRESS PRINCIPAL
OCCUPATION
<S> <C> <C>
Jean-Claude Scraire Caisse de depot et placement du Quebec Chairman
1981, avenue McGill College
Montreal (Quebec) H3A 3C7
Guy Morneau Regie des rentes du Quebec Chairman of the
2600, boul. Laurier, bureau 546 Board and
Quebec (Quebec) G1V 4T3 President
Jean-Claude Bachand Byers Casgrain Lawyer
1, Place Ville-Marie
Bureau 3900
Montreal (Quebec) H3B 4M7
Claude Beland La Confederation des Caisses populaires et President
d'economie Desjardins du Quebec
100, avenue des Commandeurs
Levis (Quebec) G6V 7N5
Luc Bessette Commission administrative des regimes President
de retraite et d'assurances
475, rue Saint-Amable
Quebec (Quebec) G1R 5X3
Rodrigue Biron Rodrigue Biron & Associes
305, chemin de la Place St-Laurent
St-Augustin-de-Desmaures
Cap-Rouge (Quebec) G1Y 3G9
Yves Filion Hydro-Quebec Deputy Chief
75, boul. Rene-Levesque Ouest Executive Officer
Montreal (Quebec) and Chief Financial
H2Z 1A4 Officer
Jean-Yves Gagnon Societe de l'assurance automobile du Quebec General Manager
333, boul. Jean-Lesage
Quebec (Quebec) G1K 8J6
Henri Masse Federation des travailleurs et travailleuses du President
Quebec
545, boul. Cremazie Est, 17(e) etage
Montreal, (Quebec) H2M 2V1
</TABLE>
10
<PAGE>
SCHEDULE 1
LIST OF EXECUTIVE OFFICERS AND DIRECTORS OF CDPQ
<TABLE>
<CAPTION>
DIRECTORS BUSINESS ADDRESS PRINCIPAL
OCCUPATION
<S> <C> <C>
Gilles Godbout Ministere des Finances Deputy Minister
12, rue St-Louis
Quebec (Quebec) G1R 5L3
Thomas O. Hecht Technologies IBEX Inc. Chairman Emeritus
5485, rue Pare
Montreal (Quebec) H4P 1P7
Gerald Larose Confederation des syndicats nationaux
1601, rue Delorimier
Montreal (Quebec) H2K 4M5
Nicole Trudeau Commission municipale du Quebec Vice-President
2, Complexe Desjardins
Suite 3100, East Tower
Montreal (Quebec) H5B 1B2
</TABLE>
11
<PAGE>
SCHEDULE 1
LIST OF EXECUTIVE OFFICERS AND DIRECTORS OF CDPQ
<TABLE>
<CAPTION>
OFFICERS BUSINESS ADDRESS PRINCIPAL
OCCUPATION
<S> <C> <C>
Jean-Claude Scraire Caisse de depot et placement du Chairman
Quebec
1981, avenue McGill College
Montreal (Quebec) H3A 3C7
Fernand Perreault Same Senior Vice-president
Caisse Real Estate
Group and Mortgage
Investments
Michel Nadeau Same Senior Vice-president
Investment Planning and
Strategic Affairs
Ginette Depelteau Same General Secretary -
Director
</TABLE>
12
<PAGE>
EXHIBIT INDEX
Exhibit
- -------
1. Joint Filing Agreement dated October 29, 1999 by and between Sofinov and
CDPQ.
2. Joint Filing Table of Sales and Purchases of Cubist Pharmaceuticals, Inc.
3. Joint Filing Table of Dates, Number of Shares sold and price per Share of
Sales.
13
<PAGE>
EXHIBIT 1
AGREEMENT
The undersigned hereby agree that this statement on Schedule 13D with
respect to beneficial ownership of shares of common stock of Cubist
Pharmaceuticals, Inc. is filed jointly, on behalf of each of them.
Dated: October 29, 1999
SOFINOV, SOCIETE FINANCIERE D'INNOVATION, INC.
By:
-----------------------------------------------
Name: Denis Dionne
Title: President
By:
-----------------------------------------------
Name: Ginette Depelteau
Title: Corporate Secretary
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC.
By:
-----------------------------------------------
Name: Michel Nadeau
Title: Senior Vice-president
Investment Planning and Strategic Affairs
By:
-----------------------------------------------
Name: Ginette Depelteau
Title: General Secretary - Director
14
<PAGE>
EXHIBIT 2
- --------------------------------------------------------------------------------
TABLE OF SALES AND PURCHASES OF
CUBIST PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
PURCHASES
- --------------------------------------------------------------------------------
PRICE PER SHARE
DATE NUMBER OF SHARES IN US DOLLARS
- ---- ---------------- -------------
<S> <C> <C>
September 1998
- --------------
10 164,000 1.75 *
23 2,222,223 2.25 *
</TABLE>
* Purchases effected in United States
15
<PAGE>
EXHIBIT 3
- --------------------------------------------------------------------------------
TABLE OF SALES OF
CUBIST PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
SALES
- ------------------------------------------------------------------------------------------------------------------------------------
PRICE PER SHARE
DATE NUMBER OF SHARES IN US DOLLARS
- ---- ---------------- -------------
<S> <C> <C>
September 1999.
- ---------------
14 500,000 10.35 *
</TABLE>
* Sales effected in United States
16
